首页 > 最新文献

Cancer Investigation最新文献

英文 中文
Does Aspirin Use Reduce the Risk for Ovarian Cancer? 服用阿司匹林会降低罹患卵巢癌的风险吗?
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-07-05 DOI: 10.1080/07357907.2024.2375573
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein

Ovarian cancer is an aggressive malignancy and the leading cause of death among gynecologic cancers. Researchers have evaluated prophylactic medications that potentially avert the manifestation of ovarian cancer, but currently, there are no reliable screening measures for this disease. Nevertheless, the largest study involving aspirin use and ovarian cancer reported a substantive risk reduction from enduring aspirin use. Since there are countervailing data to impugn the potential benefits of aspirin use in staving off ovarian cancer, further research should scrutinize the use of this medication as a prophylactic intervention, especially in women who are at higher risk for developing the disease.

卵巢癌是一种侵袭性恶性肿瘤,也是妇科癌症中的主要死因。研究人员已对可能避免卵巢癌发生的预防性药物进行了评估,但目前还没有针对这种疾病的可靠筛查措施。不过,涉及阿司匹林使用和卵巢癌的最大规模研究报告称,长期服用阿司匹林可大大降低患癌风险。由于有相反的数据对使用阿司匹林预防卵巢癌的潜在益处提出了质疑,因此进一步的研究应该对使用这种药物作为预防性干预措施进行仔细审查,尤其是对那些罹患该疾病风险较高的妇女。
{"title":"Does Aspirin Use Reduce the Risk for Ovarian Cancer?","authors":"John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein","doi":"10.1080/07357907.2024.2375573","DOIUrl":"https://doi.org/10.1080/07357907.2024.2375573","url":null,"abstract":"<p><p>Ovarian cancer is an aggressive malignancy and the leading cause of death among gynecologic cancers. Researchers have evaluated prophylactic medications that potentially avert the manifestation of ovarian cancer, but currently, there are no reliable screening measures for this disease. Nevertheless, the largest study involving aspirin use and ovarian cancer reported a substantive risk reduction from enduring aspirin use. Since there are countervailing data to impugn the potential benefits of aspirin use in staving off ovarian cancer, further research should scrutinize the use of this medication as a prophylactic intervention, especially in women who are at higher risk for developing the disease.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Investigational Drug's Targeting Various Molecular Pathways for Treatment of Cervical Cancer: Current Status and Future Prospects. 针对各种分子途径治疗宫颈癌的新型研究药物:现状与前景
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-07-05 DOI: 10.1080/07357907.2024.2373841
Rakesh Kumar Kore, Ekta Shirbhate, Vaibhav Singh, Achal Mishra, Ravichandran Veerasamy, Harish Rajak

Currently, cervical cancer (CC) is the fourth recorded widespread cancer among women globally. There are still many cases of metastatic or recurring disease discovered, despite the incidence and fatality rates declining due to screening identification and innovative treatment approaches. Palliative chemotherapy continues to be the standard of care for patients who are not contenders for curative therapies like surgery and radiotherapy. This article seeks to provide a thorough and current summary of therapies that have been looked into for the management of CC. The authors emphasize the ongoing trials while reviewing the findings of clinical research. Agents that use biological mechanisms to target different molecular pathways such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR), poly ADP-ribosepolymerase (PARP), and epigenetic biological mechanisms epitomize and offer intriguing research prospects.

目前,宫颈癌(CC)是全球妇女第四大常见癌症。尽管由于筛查识别和创新治疗方法,发病率和死亡率有所下降,但仍有许多转移或复发病例被发现。对于无法接受手术和放疗等根治性疗法的患者,姑息化疗仍然是标准的治疗方法。本文旨在全面总结目前治疗CC的疗法。作者在回顾临床研究结果的同时,还强调了正在进行的试验。利用生物机制靶向不同分子通路的药物,如表皮生长因子受体(EGFR)、血管内皮生长因子(VEGF)、哺乳动物雷帕霉素靶点(mTOR)、多聚 ADP-核糖聚合酶(PARP)和表观遗传生物机制等,是研究前景引人入胜的缩影。
{"title":"New Investigational Drug's Targeting Various Molecular Pathways for Treatment of Cervical Cancer: Current Status and Future Prospects.","authors":"Rakesh Kumar Kore, Ekta Shirbhate, Vaibhav Singh, Achal Mishra, Ravichandran Veerasamy, Harish Rajak","doi":"10.1080/07357907.2024.2373841","DOIUrl":"https://doi.org/10.1080/07357907.2024.2373841","url":null,"abstract":"<p><p>Currently, cervical cancer (CC) is the fourth recorded widespread cancer among women globally. There are still many cases of metastatic or recurring disease discovered, despite the incidence and fatality rates declining due to screening identification and innovative treatment approaches. Palliative chemotherapy continues to be the standard of care for patients who are not contenders for curative therapies like surgery and radiotherapy. This article seeks to provide a thorough and current summary of therapies that have been looked into for the management of CC. The authors emphasize the ongoing trials while reviewing the findings of clinical research. Agents that use biological mechanisms to target different molecular pathways such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR), poly ADP-ribosepolymerase (PARP), and epigenetic biological mechanisms epitomize and offer intriguing research prospects.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gustative Roussy Immune Score is a Predictor for Major Pathological Response in Rectal Cancer: A Result from the Preoperative Intraarterial Chemoembolization Combined with Radiotherapy (PCAR) Study. Gustative Roussy 免疫评分是直肠癌主要病理反应的预测指标:术前动脉内化疗栓塞联合放疗(PCAR)研究结果。
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-07-05 DOI: 10.1080/07357907.2024.2366912
Wei-Na Yang, Xue-Mei Li, Chao-Fan Li, Chuan Chen, Yan Feng, Nan Dai, Yu-Xin Yang, Meng-Xia Li, Chun-Xue Li, Cheng-Yuan Qian, Dong Wang, He Xiao, Jia-Min Luo

Despite the emergence of various treatment strategies for rectal cancer based on neoadjuvant chemoradiotherapy, there is currently a lack of reliable biomarkers to determine which patients will respond well to neoadjuvant chemoradiotherapy. Through collecting hematological and biochemical parameters data of patients prior to receiving neoadjuvant chemoradiotherapy, we evaluated the predictive value of systemic inflammatory indices for pathological response and prognosis in rectal cancer patients. We found that baseline GRIm-Score was an independent predictor for MPR in rectal cancer patients. However, no association was observed between several commonly systemic inflammation indices and long-term outcome.

尽管出现了基于新辅助化放疗的各种直肠癌治疗策略,但目前缺乏可靠的生物标志物来确定哪些患者对新辅助化放疗反应良好。通过收集患者接受新辅助化放疗前的血液学和生化指标数据,我们评估了全身炎症指标对直肠癌患者病理反应和预后的预测价值。我们发现,基线 GRIm-Score 是直肠癌患者 MPR 的独立预测因子。然而,在几种常见的全身炎症指数与长期预后之间没有观察到任何关联。
{"title":"Gustative Roussy Immune Score is a Predictor for Major Pathological Response in Rectal Cancer: A Result from the Preoperative Intraarterial Chemoembolization Combined with Radiotherapy (PCAR) Study.","authors":"Wei-Na Yang, Xue-Mei Li, Chao-Fan Li, Chuan Chen, Yan Feng, Nan Dai, Yu-Xin Yang, Meng-Xia Li, Chun-Xue Li, Cheng-Yuan Qian, Dong Wang, He Xiao, Jia-Min Luo","doi":"10.1080/07357907.2024.2366912","DOIUrl":"https://doi.org/10.1080/07357907.2024.2366912","url":null,"abstract":"<p><p>Despite the emergence of various treatment strategies for rectal cancer based on neoadjuvant chemoradiotherapy, there is currently a lack of reliable biomarkers to determine which patients will respond well to neoadjuvant chemoradiotherapy. Through collecting hematological and biochemical parameters data of patients prior to receiving neoadjuvant chemoradiotherapy, we evaluated the predictive value of systemic inflammatory indices for pathological response and prognosis in rectal cancer patients. We found that baseline GRIm-Score was an independent predictor for MPR in rectal cancer patients. However, no association was observed between several commonly systemic inflammation indices and long-term outcome.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial Intelligence and Cancer Clinical Research: III Risk Prediction Models for Febrile Neutropenia in Patients Receiving Cancer Chemotherapy. 人工智能与癌症临床研究:癌症化疗患者发热性中性粒细胞减少症的 III 风险预测模型。
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-07-04 DOI: 10.1080/07357907.2024.2370692
Gary H Lyman, Nicole M Kuderer
{"title":"Artificial Intelligence and Cancer Clinical Research: III Risk Prediction Models for Febrile Neutropenia in Patients Receiving Cancer Chemotherapy.","authors":"Gary H Lyman, Nicole M Kuderer","doi":"10.1080/07357907.2024.2370692","DOIUrl":"https://doi.org/10.1080/07357907.2024.2370692","url":null,"abstract":"","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Myeloproliferative Neoplasms Transcriptome Reveals Pro-Inflammatory Signature and Enrichment in Peripheral Blood Monocyte-Related Genes. 骨髓增生性肿瘤转录组显示促炎症特征和丰富的外周血单核细胞相关基因
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-07-03 DOI: 10.1080/07357907.2024.2371371
Vitor Leonardo Bassan, Rafaela de Freitas Martins Felício, Kelen Cristina Ribeiro Malmegrim de Farias, Fabíola Attié de Castro

Myeloproliferative neoplasms (MPN) are hematological diseases associated with genetic driver mutations in the JAK2, CALR, and MPL genes and exacerbated oncoinflammatory status. Analyzing public microarray data from polycythemia vera (n = 41), essential thrombocythemia (n = 21), and primary myelofibrosis (n = 9) patients' peripheral blood by in silico approaches, we found that pro-inflammatory and monocyte-related genes were differentially expressed in MPN patients' transcriptome. Genes related to cell activation, secretion of pro-inflammatory and pro-angiogenic mediators, activation of neutrophils and platelets, coagulation, and interferon pathway were upregulated in monocytes compared to controls. Together, our results suggest that molecular alterations in monocytes may contribute to oncoinflammation in MPN.

骨髓增生性肿瘤(MPN)是一种血液病,与 JAK2、CALR 和 MPL 基因的遗传驱动突变有关,并因生态炎症状态而加重。我们通过硅学方法分析了来自真性红细胞增多症(41 例)、原发性血小板增多症(21 例)和原发性骨髓纤维化(9 例)患者外周血的公开芯片数据,发现在 MPN 患者的转录组中,促炎症基因和单核细胞相关基因有差异表达。与对照组相比,单核细胞中与细胞活化、促炎症和促血管生成介质的分泌、中性粒细胞和血小板的活化、凝血和干扰素通路相关的基因上调。总之,我们的研究结果表明,单核细胞的分子改变可能是导致 MPN 生态炎症的原因之一。
{"title":"Myeloproliferative Neoplasms Transcriptome Reveals Pro-Inflammatory Signature and Enrichment in Peripheral Blood Monocyte-Related Genes.","authors":"Vitor Leonardo Bassan, Rafaela de Freitas Martins Felício, Kelen Cristina Ribeiro Malmegrim de Farias, Fabíola Attié de Castro","doi":"10.1080/07357907.2024.2371371","DOIUrl":"https://doi.org/10.1080/07357907.2024.2371371","url":null,"abstract":"<p><p>Myeloproliferative neoplasms (MPN) are hematological diseases associated with genetic driver mutations in the JAK2, CALR, and MPL genes and exacerbated oncoinflammatory <i>status</i>. Analyzing public microarray data from polycythemia vera (n = 41), essential thrombocythemia (n = 21), and primary myelofibrosis (n = 9) patients' peripheral blood by <i>in silico</i> approaches, we found that pro-inflammatory and monocyte-related genes were differentially expressed in MPN patients' transcriptome. Genes related to cell activation, secretion of pro-inflammatory and pro-angiogenic mediators, activation of neutrophils and platelets, coagulation, and interferon pathway were upregulated in monocytes compared to controls. Together, our results suggest that molecular alterations in monocytes may contribute to oncoinflammation in MPN.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elevated Vitamin B12, Risk of Cancer, and Mortality: A Systematic Review. 维生素 B12 升高、癌症风险和死亡率:系统回顾
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-07-02 DOI: 10.1080/07357907.2024.2366907
Sandra B Amado-Garzon, Luisana Molina-Pimienta, Andrea Vejarano-Pombo, Mariana Vélez-Bonilla, Jaime Moreno-Chaparro, Adriana Buitrago-Lopez

Vitamin B12 (B12) is a molecule involved in several biological. Abnormally high levels are frequently found, but their causes can be multiple, and consequences have not been clearly elucidated. The objective of this review was to summarize the current evidence on the associations of elevated B12 and the development of cancer, and all-cause mortality in adults. Six references looking at mortality and seven looking at cancer risk were included. The evidence suggests an association between elevated B12 with a higher risk of cancer, with risk ratios ranging 1,88 to 5,9. There was less consistent evidence linking vitamin B12 and mortality.

维生素 B12(B12)是一种参与多种生物学活动的分子。维生素 B12 含量异常升高的现象屡见不鲜,但其原因可能是多方面的,其后果也尚未明确阐明。本综述旨在总结目前有关 B12 升高与癌症发病和成人全因死亡率之间关系的证据。其中包括六篇研究死亡率的参考文献和七篇研究癌症风险的参考文献。证据表明,B12 升高与癌症风险增加之间存在关联,风险比从 1.88 到 5.9 不等。而将维生素 B12 与死亡率联系起来的证据则不那么一致。
{"title":"Elevated Vitamin B12, Risk of Cancer, and Mortality: A Systematic Review.","authors":"Sandra B Amado-Garzon, Luisana Molina-Pimienta, Andrea Vejarano-Pombo, Mariana Vélez-Bonilla, Jaime Moreno-Chaparro, Adriana Buitrago-Lopez","doi":"10.1080/07357907.2024.2366907","DOIUrl":"https://doi.org/10.1080/07357907.2024.2366907","url":null,"abstract":"<p><p>Vitamin B12 (B12) is a molecule involved in several biological. Abnormally high levels are frequently found, but their causes can be multiple, and consequences have not been clearly elucidated. The objective of this review was to summarize the current evidence on the associations of elevated B12 and the development of cancer, and all-cause mortality in adults. Six references looking at mortality and seven looking at cancer risk were included. The evidence suggests an association between elevated B12 with a higher risk of cancer, with risk ratios ranging 1,88 to 5,9. There was less consistent evidence linking vitamin B12 and mortality.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barthel Index and Age as Predictors of Discharge Destination in Patients with Glioblastoma. 作为胶质母细胞瘤患者出院去向预测因素的巴特尔指数和年龄
IF 1.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-06-27 DOI: 10.1080/07357907.2024.2371367
Hirotomo Shibahashi, Miyuki Murakawa, Kenichiro Matsuda, Yuya Takakubo, Michiaki Takagi

This study aimed to investigate the predictive factors of transfer of glioblastoma multiforme (GBM) patients who underwent rehabilitation in acute care hospitals. We retrospectively identified 85 patients with GBM who underwent rehabilitation at our hospital. Multivariable logistic regression analysis showed that age and Barthel index (BI) at rehabilitation initiation significantly influenced the discharge destination. Cut-off values for these factors were 76 years of age and 30 BI points. These findings could help predict the discharge destination and the choice of rehabilitation strategies of newly diagnosed patients with GBM admitted to an acute care hospital.

本研究旨在调查在急诊医院接受康复治疗的多形性胶质母细胞瘤(GBM)患者转院的预测因素。我们回顾性地确定了85名在本院接受康复治疗的多形性胶质母细胞瘤患者。多变量逻辑回归分析表明,开始康复时的年龄和巴特尔指数(BI)对出院去向有显著影响。这些因素的临界值为 76 岁和 30 个 BI 点。这些发现有助于预测入住急症医院的新确诊 GBM 患者的出院去向和康复策略的选择。
{"title":"Barthel Index and Age as Predictors of Discharge Destination in Patients with Glioblastoma.","authors":"Hirotomo Shibahashi, Miyuki Murakawa, Kenichiro Matsuda, Yuya Takakubo, Michiaki Takagi","doi":"10.1080/07357907.2024.2371367","DOIUrl":"https://doi.org/10.1080/07357907.2024.2371367","url":null,"abstract":"<p><p>This study aimed to investigate the predictive factors of transfer of glioblastoma multiforme (GBM) patients who underwent rehabilitation in acute care hospitals. We retrospectively identified 85 patients with GBM who underwent rehabilitation at our hospital. Multivariable logistic regression analysis showed that age and Barthel index (BI) at rehabilitation initiation significantly influenced the discharge destination. Cut-off values for these factors were 76 years of age and 30 BI points. These findings could help predict the discharge destination and the choice of rehabilitation strategies of newly diagnosed patients with GBM admitted to an acute care hospital.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141455500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Prophylactic Post-Chemotherapy G-CSF on the Relapse Rates in Patients with Acute Myeloid Leukemia: A Meta-Analysis. 化疗后预防性使用 G-CSF 对急性髓性白血病患者复发率的影响:一项 Meta 分析
IF 1.8 4区 医学 Q3 Medicine Pub Date : 2024-06-26 DOI: 10.1080/07357907.2024.2352454
Mohammadreza Bordbar, Mahnaz Hosseini-Bensenjan, Mehrab Sayadi, Omidreza Zekavat, Shayan Bordbar, Farnoosh Nozari, Sezaneh Haghpanah

This meta-analysis evaluated the impact of prophylactic post-chemotherapy granulocyte colony-stimulating factor (G-CSF) in patients with acute myeloid leukemia (AML). Overall, the relapse rate, overall survival, event-free survival, and mortality rate were similar in G-CSF (+) compared to G-CSF (-) patients. However, the relative risk (RR) of relapse was higher in children and in secondary AML patients who were treated with G-CSF compared to the G-CSF (-) group [RR, 95% confidence interval: 1.26, 1.04-1.52, and 1.12 (1.02-1.24)]. Treatment with post-chemotherapy G-CSF should be prescribed with caution in pediatric patients with AML and secondary AML as possibly increasing the relapse risk.

这项荟萃分析评估了急性髓性白血病(AML)患者化疗后预防性使用粒细胞集落刺激因子(G-CSF)的影响。总体而言,G-CSF(+)与G-CSF(-)患者的复发率、总生存率、无事件生存率和死亡率相似。然而,与G-CSF(-)组相比,接受G-CSF治疗的儿童和继发性AML患者的复发相对风险(RR)更高[RR,95%置信区间:1.26、1.04-1.52和1.12(1.02-1.24)]。对于急性髓细胞性白血病和继发性急性髓细胞性白血病的儿童患者,化疗后使用G-CSF治疗应慎重,因为这可能会增加复发风险。
{"title":"The Impact of Prophylactic Post-Chemotherapy G-CSF on the Relapse Rates in Patients with Acute Myeloid Leukemia: A Meta-Analysis.","authors":"Mohammadreza Bordbar, Mahnaz Hosseini-Bensenjan, Mehrab Sayadi, Omidreza Zekavat, Shayan Bordbar, Farnoosh Nozari, Sezaneh Haghpanah","doi":"10.1080/07357907.2024.2352454","DOIUrl":"https://doi.org/10.1080/07357907.2024.2352454","url":null,"abstract":"<p><p>This meta-analysis evaluated the impact of prophylactic post-chemotherapy granulocyte colony-stimulating factor (G-CSF) in patients with acute myeloid leukemia (AML). Overall, the relapse rate, overall survival, event-free survival, and mortality rate were similar in G-CSF (+) compared to G-CSF (-) patients. However, the relative risk (RR) of relapse was higher in children and in secondary AML patients who were treated with G-CSF compared to the G-CSF (-) group [RR, 95% confidence interval: 1.26, 1.04-1.52, and 1.12 (1.02-1.24)]. Treatment with post-chemotherapy G-CSF should be prescribed with caution in pediatric patients with AML and secondary AML as possibly increasing the relapse risk.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141449755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fusobacterium Detected in Barrett's Esophagus and Esophageal Adenocarcinoma Tissues. 在巴雷特食管和食管腺癌组织中检测到镰刀菌
IF 1.8 4区 医学 Q3 Medicine Pub Date : 2024-06-24 DOI: 10.1080/07357907.2024.2359980
Tomomitsu Tahara, Takuya Shijimaya, Jumpei Yamazaki, Sanshiro Kobayashi, Anna Horitani, Yasushi Matsumoto, Naohiro Nakamura, Takashi Okazaki, Yu Takahashi, Takashi Tomiyama, Yusuke Honzawa, Norimasa Fukata, Toshiro Fukui, Makoto Naganuma

We examined Fusobacterium nucreatum (F. nucleatum) and whole Fusobacterium species (Pan-fusobacterium) in non-neoplastic Barrett's esophagus (BE) from patients without cancer (n = 67; N group), with esophageal adenocarcinoma (EAC) (n = 27) and EAC tissue (n = 22). F. nucleatum was only detectable in 22.7% of EAC tissue. Pan-fusobacterium was enriched in EAC tissue and associated with aggressive clinicopathological features. Amount of Pan-fusobacterium in non-neoplastic BE was correlated with presence of hital hernia and telomere shortening. The result suggested potential association of Fusobacterium species in EAC and BE, featuring clinicpathological and molecular features.

我们检测了非肿瘤性巴雷特食管(BE)患者(n = 67;N 组)、食管腺癌(EAC)患者(n = 27)和 EAC 组织(n = 22)中的核仁镰刀菌(F. nucleatum)和整个镰刀菌种(Pan-fusobacterium)。仅在 22.7% 的 EAC 组织中检测到核酸酵母菌。泛螺旋体在EAC组织中富集,并与侵袭性临床病理特征相关。非肿瘤性 BE 中的泛镰状杆菌数量与疝和端粒缩短相关。结果表明,EAC和BE中的镰刀菌可能与临床病理和分子特征有关。
{"title":"Fusobacterium Detected in Barrett's Esophagus and Esophageal Adenocarcinoma Tissues.","authors":"Tomomitsu Tahara, Takuya Shijimaya, Jumpei Yamazaki, Sanshiro Kobayashi, Anna Horitani, Yasushi Matsumoto, Naohiro Nakamura, Takashi Okazaki, Yu Takahashi, Takashi Tomiyama, Yusuke Honzawa, Norimasa Fukata, Toshiro Fukui, Makoto Naganuma","doi":"10.1080/07357907.2024.2359980","DOIUrl":"https://doi.org/10.1080/07357907.2024.2359980","url":null,"abstract":"<p><p>We examined <i>Fusobacterium nucreatum</i> (<i>F. nucleatum</i>) and whole <i>Fusobacterium species</i> (<i>Pan-fusobacterium</i>) in non-neoplastic Barrett's esophagus (BE) from patients without cancer (<i>n</i> = 67; N group), with esophageal adenocarcinoma (EAC) (<i>n</i> = 27) and EAC tissue (<i>n</i> = 22). <i>F. nucleatum</i> was only detectable in 22.7% of EAC tissue. <i>Pan-fusobacterium</i> was enriched in EAC tissue and associated with aggressive clinicopathological features. Amount of <i>Pan-fusobacterium</i> in non-neoplastic BE was correlated with presence of hital hernia and telomere shortening. The result suggested potential association of <i>Fusobacterium species</i> in EAC and BE, featuring clinicpathological and molecular features.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Bioinformatic Analysis of Gut Microbiota Related with Immune Cell Infiltration in Colorectal Cancer. 结直肠癌免疫细胞浸润相关肠道微生物群的生物信息学分析
IF 1.8 4区 医学 Q3 Medicine Pub Date : 2024-06-21 DOI: 10.1080/07357907.2024.2368233
Dan Liu, Jiang Zhou, Qiong Fu, Yuanzhu Zhao, Panpan Wang, Yang Zheng, Meihong Cui, Heng Zhang

Objective: The composition of microbiota which correlates with infiltrating immune cells and clinical signatures is not clarified in CRC.

Methods: We applied 4 kinds of bioinformatic tools GSVA (version: 1.42.0), ESTIMATE (version: 1.0.13), CIBERSORT (version: 2.0), and immune-related genes.

Results: We found that a total of 8 types of microbiotas appeared in the three immune correlation analyses. Among these microbiotas, significant enrichments in relative abundances associated with immune cell infiltration can be found for the dominant phyla Proteobacteria, Firmicutes, and Actinobacteria. Moreover, there existed correlations between some of the 8 microbiotas and clinical-related indicators.

Conclusion: We identified some novel microbiotas involved in immune regulation in CRC.

摘要CRC中与浸润免疫细胞和临床特征相关的微生物群组成尚未明确:我们应用了4种生物信息学工具GSVA(版本:1.42.0)、ESTIMATE(版本:1.0.13)、CIBERSORT(版本:2.0)和免疫相关基因:结果:我们发现共有 8 种微生物群出现在三种免疫相关性分析中。在这些微生物群中,主要的变形菌门、固形菌门和放线菌门与免疫细胞浸润相关的相对丰度明显增加。此外,8 个微生物群中的一些微生物群与临床相关指标之间存在相关性:结论:我们发现了一些参与 CRC 免疫调节的新型微生物群。
{"title":"A Bioinformatic Analysis of Gut Microbiota Related with Immune Cell Infiltration in Colorectal Cancer.","authors":"Dan Liu, Jiang Zhou, Qiong Fu, Yuanzhu Zhao, Panpan Wang, Yang Zheng, Meihong Cui, Heng Zhang","doi":"10.1080/07357907.2024.2368233","DOIUrl":"10.1080/07357907.2024.2368233","url":null,"abstract":"<p><strong>Objective: </strong>The composition of microbiota which correlates with infiltrating immune cells and clinical signatures is not clarified in CRC.</p><p><strong>Methods: </strong>We applied 4 kinds of bioinformatic tools GSVA (version: 1.42.0), ESTIMATE (version: 1.0.13), CIBERSORT (version: 2.0), and immune-related genes.</p><p><strong>Results: </strong>We found that a total of 8 types of microbiotas appeared in the three immune correlation analyses. Among these microbiotas, significant enrichments in relative abundances associated with immune cell infiltration can be found for the dominant phyla Proteobacteria, Firmicutes, and Actinobacteria. Moreover, there existed correlations between some of the 8 microbiotas and clinical-related indicators.</p><p><strong>Conclusion: </strong>We identified some novel microbiotas involved in immune regulation in CRC.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Investigation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1